159 related articles for article (PubMed ID: 30548777)
21. Allopurinol to Prevent Mercaptopurine Adverse Effects in Children and Young Adults With Acute Lymphoblastic Leukemia.
Kamojjala R; Bostrom B
J Pediatr Hematol Oncol; 2021 Apr; 43(3):95-100. PubMed ID: 33750748
[TBL] [Abstract][Full Text] [Related]
22. The association between fasting hypoglycemia and methylated mercaptopurine metabolites in children with acute lymphoblastic leukemia.
Melachuri S; Gandrud L; Bostrom B
Pediatr Blood Cancer; 2014 Jun; 61(6):1003-6. PubMed ID: 24415675
[TBL] [Abstract][Full Text] [Related]
23. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?
Meijer B; Seinen ML; van Egmond R; Bouma G; Mulder CJJ; van Bodegraven AA; de Boer NKH
Inflamm Bowel Dis; 2017 Nov; 23(11):2011-2017. PubMed ID: 28617756
[TBL] [Abstract][Full Text] [Related]
24. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
[TBL] [Abstract][Full Text] [Related]
25. Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol-Thiopurine Combination Therapy.
Seinen ML; van Asseldonk DP; de Boer NK; Bouma G; van Nieuwkerk CM; Mulder CJ; Bloemena E; van Bodegraven AA
Inflamm Bowel Dis; 2017 Mar; 23(3):448-452. PubMed ID: 28151736
[TBL] [Abstract][Full Text] [Related]
26. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.
Dubinsky MC; Yang H; Hassard PV; Seidman EG; Kam LY; Abreu MT; Targan SR; Vasiliauskas EA
Gastroenterology; 2002 Apr; 122(4):904-15. PubMed ID: 11910342
[TBL] [Abstract][Full Text] [Related]
27. Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease.
Sparrow MP
Gastroenterol Hepatol (N Y); 2008 Jul; 4(7):505-11. PubMed ID: 21960930
[TBL] [Abstract][Full Text] [Related]
28. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia.
Chrzanowska M; Kolecki P; Duczmal-Cichocka B; Fiet J
Eur J Pharm Sci; 1999 Aug; 8(4):329-34. PubMed ID: 10425383
[TBL] [Abstract][Full Text] [Related]
29. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?
Lennard L; Davies HA; Lilleyman JS
Br J Cancer; 1993 Jul; 68(1):186-90. PubMed ID: 8318412
[TBL] [Abstract][Full Text] [Related]
30. Transport and metabolism of 6-thioguanine and 6-mercaptopurine in mouse small intestine.
Bronk JR; Lister N; Shaw MI
Clin Sci (Lond); 1988 Jun; 74(6):629-38. PubMed ID: 3396300
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose.
Welch J; Lennard L; Morton GC; Lilleyman JS
Ther Drug Monit; 1997 Aug; 19(4):382-5. PubMed ID: 9263376
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of allopurinol induced TPMT inhibition.
Blaker PA; Arenas-Hernandez M; Smith MA; Shobowale-Bakre EA; Fairbanks L; Irving PM; Sanderson JD; Marinaki AM
Biochem Pharmacol; 2013 Aug; 86(4):539-47. PubMed ID: 23770457
[TBL] [Abstract][Full Text] [Related]
33. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting.
Mardini HE; Arnold GL
J Clin Gastroenterol; 2003; 36(5):390-5. PubMed ID: 12702978
[TBL] [Abstract][Full Text] [Related]
34. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism.
Lennard L; Lilleyman JS
Ther Drug Monit; 1996 Aug; 18(4):328-34. PubMed ID: 8857546
[TBL] [Abstract][Full Text] [Related]
35. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
Leong RW; Gearry RB; Sparrow MP
Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
[TBL] [Abstract][Full Text] [Related]
36. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase.
Krynetski EY; Krynetskaia NF; Yanishevski Y; Evans WE
Mol Pharmacol; 1995 Jun; 47(6):1141-7. PubMed ID: 7603453
[TBL] [Abstract][Full Text] [Related]
37. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.
Evans WE; Horner M; Chu YQ; Kalwinsky D; Roberts WM
J Pediatr; 1991 Dec; 119(6):985-9. PubMed ID: 1960624
[TBL] [Abstract][Full Text] [Related]
38. Severe mercaptopurine-induced hypoglycemia in acute lymphoblastic leukemia.
Rebelo A; Oliveira J; Sousa C
Pediatr Hematol Oncol; 2020 Apr; 37(3):245-247. PubMed ID: 31984843
[TBL] [Abstract][Full Text] [Related]
39. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.
Cuffari C; Théorêt Y; Latour S; Seidman G
Gut; 1996 Sep; 39(3):401-6. PubMed ID: 8949645
[TBL] [Abstract][Full Text] [Related]
40. Differential role of thiopurine methyltransferase in the cytotoxic effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells.
Karim H; Ghalali A; Lafolie P; Vitols S; Fotoohi AK
Biochem Biophys Res Commun; 2013 Jul; 437(2):280-6. PubMed ID: 23811272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
